Status:
COMPLETED
A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections
Lead Sponsor:
Pfizer
Conditions:
Candidiasis
Cryptococcosis
Eligibility:
All Genders
12+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of Vfend for the treatment of fungal infections
Eligibility Criteria
Inclusion
- Systemic or invasive fungal infection
- Infection caused by organism for which there is no current treatment or infection with evidence of failure and/or intolerance to treatment with approved antifungal agents
Exclusion
- Liver function test abnormalities
- Renal disease
- Fungal infections not considered to be invasive or systemic
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2004
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00647907
Start Date
April 1 2003
End Date
May 1 2004
Last Update
May 16 2011
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Kaohsiung City, Taiwan
2
Pfizer Investigational Site
Taichung, Taiwan, 40705
3
Pfizer Investigational Site
Taipei, Taiwan, 100
4
Pfizer Investigational Site
Taipei, Taiwan, 114